5 results
8-K
EX-99.1
PULM
Pulmatrix Inc
28 Mar 24
Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update
9:05am
equivalents provide projected cash runway into Q1 2026
3rd amendment to Cipla partnership resulted in the wind down of the PUR1900 Phase 2b study … since the first quarter of 2023. The Company expects to complete all Phase 2b activities by the third quarter of 2024.
After the study wind down
8-K
EX-10.1
PULM
Pulmatrix Inc
8 Jan 24
Entry into a Material Definitive Agreement
9:00am
with such site transfer to the extent that such cost is solely incurred with respect to the Cipla Territory shall be paid by Cipla in the Wind Down Phase Funding … commencing on the Effective Date and ending July 30, 2024 (the “Wind Down Period”); the Parties agree to do the following, at no extra cost to Cipla
8-K
PULM
Pulmatrix Inc
8 Jan 24
Entry into a Material Definitive Agreement
9:00am
as reasonably possible. In connection with the termination of the Phase 2b Clinical Study (the “Development Wind Down Plan”), the Company and Cipla will each … on development of the Product (the “Direct Costs”) associated with the Development Wind Down Plan, and (ii) 50% each for all of the other development costs
8-K
EX-10.1
PULM
Pulmatrix Inc
15 Apr 20
Entry into a Material Definitive Agreement
5:02pm
to Pulmatrix;provided that if Sensory Cloud exercises its rights under this Section 10.2(b) it shall cooperate with Pulmatrix in good faith to wind
- Prev
- 1
- Next